EA201100157A1 - Лиганд с широким спектром фармакологической активности, фармацевтическая композиция, лекарственное средство и способ лечения - Google Patents

Лиганд с широким спектром фармакологической активности, фармацевтическая композиция, лекарственное средство и способ лечения

Info

Publication number
EA201100157A1
EA201100157A1 EA201100157A EA201100157A EA201100157A1 EA 201100157 A1 EA201100157 A1 EA 201100157A1 EA 201100157 A EA201100157 A EA 201100157A EA 201100157 A EA201100157 A EA 201100157A EA 201100157 A1 EA201100157 A1 EA 201100157A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
ligand
pharmacological activity
wide spectrum
drug
Prior art date
Application number
EA201100157A
Other languages
English (en)
Other versions
EA018788B1 (ru
Inventor
Андрей Александрович ИВАЩЕНКО
Александр Васильевич ИВАЩЕНКО
Николай Филиппович САВЧУК
Original Assignee
Андрей Александрович ИВАЩЕНКО
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Андрей Александрович ИВАЩЕНКО filed Critical Андрей Александрович ИВАЩЕНКО
Publication of EA201100157A1 publication Critical patent/EA201100157A1/ru
Publication of EA018788B1 publication Critical patent/EA018788B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Данное изобретение относится к новому лиганду с широким спектром фармакологической активности, в том числе по отношению к GPCR рецепторам, ионным каналам и моноаминовым транспортерам, представляющему собой 3-метил-9-бензил-1,2,3,4-тетрагидрокарболина нафталин-1,5-дисульфонат формулы 1Изобретение также относится к новому лекарственному началу, к фармацевтической композиции, содержащей новое лекарственное начало, и способу ее получения, к новым лекарственным средствам и способу лечения заболеваний центральной нервной системы (ЦНС), в том числе нейродегенеративных заболеваний и когнитивных расстройств людей и теплокровных животных.
EA201100157A 2008-08-22 2009-08-03 Лиганд с широким спектром фармакологической активности и его применение EA018788B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2008134309/04A RU2374245C1 (ru) 2008-08-22 2008-08-22 Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство
PCT/RU2009/000381 WO2010024717A1 (ru) 2008-08-22 2009-08-03 Лиганд с широким спектром фармакологической активности, фармацевтическая композиция, лекарственное средство и способ лечения

Publications (2)

Publication Number Publication Date
EA201100157A1 true EA201100157A1 (ru) 2011-08-30
EA018788B1 EA018788B1 (ru) 2013-10-30

Family

ID=41476649

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100157A EA018788B1 (ru) 2008-08-22 2009-08-03 Лиганд с широким спектром фармакологической активности и его применение

Country Status (6)

Country Link
US (1) US20110136853A1 (ru)
EP (1) EP2327703A4 (ru)
JP (1) JP2012500790A (ru)
EA (1) EA018788B1 (ru)
RU (1) RU2374245C1 (ru)
WO (1) WO2010024717A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047074T2 (hu) * 2011-06-24 2020-04-28 Arctos Medical AG Fényérzékeny kiméra GPCR fehérje
CN115998724B (zh) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG17786A3 (ru) 1970-08-14 1973-12-25
DE3402392A1 (de) 1984-01-25 1985-08-01 Sandoz-Patent-GmbH, 7850 Lörrach Neue ergolinderivate, deren herstellung und deren verwendung
JPH0667935B2 (ja) 1986-07-28 1994-08-31 マルコ製薬株式会社 エルゴリン誘導体およびその酸付加塩
JPH08239327A (ja) * 1995-03-03 1996-09-17 Taisho Pharmaceut Co Ltd 慢性骨格筋疼痛の予防又は治療剤
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
RU2140417C1 (ru) * 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
EP0905136A1 (en) 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
HUP0101057A3 (en) 1998-03-02 2001-09-28 Schering Corp Use of d1/d5 antagonists for preparing pharmaceutical compositions for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism
US6063803A (en) 1998-06-16 2000-05-16 Ortho-Mcneil Pharmaceutical, Inc. Octahydropyrrolo-[3,4-c]carbazoles useful as analgesic agents
US20020002175A1 (en) 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US7691847B2 (en) * 2002-10-17 2010-04-06 The Trustees Of The University Of Pennsylvania Method of treating neurological diseases and disorders
CA2528774A1 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
CN1590387A (zh) * 2003-08-29 2005-03-09 上海子能高科股份有限公司 一种美海洛林－1.5萘二磺酸盐的制备方法
CN100345848C (zh) 2003-09-29 2007-10-31 中国科学院上海药物研究所 左旋卤代斯库利啉盐及其制备方法和用途
RU2283108C2 (ru) * 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
EP1595542A1 (en) 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US20070254906A1 (en) 2004-07-21 2007-11-01 Darpharma, Inc. Method of Administration of Dopamine Receptor Agonists
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
US20070066594A1 (en) 2005-08-15 2007-03-22 Macdonald Peter L Crystalline forms fenoldopam mesylate
RU2338537C2 (ru) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2329044C1 (ru) * 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
WO2008133884A2 (en) * 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
JP2011507835A (ja) * 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用

Also Published As

Publication number Publication date
EA018788B1 (ru) 2013-10-30
RU2374245C1 (ru) 2009-11-27
US20110136853A1 (en) 2011-06-09
JP2012500790A (ja) 2012-01-12
EP2327703A1 (en) 2011-06-01
EP2327703A4 (en) 2012-01-04
WO2010024717A1 (ru) 2010-03-04

Similar Documents

Publication Publication Date Title
EA201200002A1 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
EA201170976A1 (ru) Получение и виды терапевтического применения (2s,3r)-n-2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)-3,5-дифторбензамида
EA201201541A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ
ATE525351T1 (de) Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung
BR112015001028A2 (pt) antagonistas de receptor 5-ht3
CY1115278T1 (el) Παραγωγα 2-αρυλιμιδαζολης ως αναστολεις του ενζυμου ρdε10α
EA200602115A1 (ru) Опиоидные соединения, замещенные карбоксамидогруппой
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
US20210198218A1 (en) Compounds for therapeutic use
ATE537143T1 (de) Spiro(5.5)undecan derivate
Sadek et al. Anticonvulsant effects of isomeric nonimidazole histamine H3 receptor antagonists
Kowalczyk et al. 2-Substituted 4-hydroxybutanamides as potential inhibitors of γ-aminobutyric acid transporters mGAT1–mGAT4: synthesis and biological evaluation
EA201100157A1 (ru) Лиганд с широким спектром фармакологической активности, фармацевтическая композиция, лекарственное средство и способ лечения
Sromek et al. Preliminary pharmacological evaluation of enantiomeric morphinans
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.
Demin et al. Acute behavioral and neurochemical effects of novel n-benzyl-2-phenylethylamine derivatives in adult zebrafish
GB2470495A (en) Oxazolidine derivatives as NMDA antagonists
EA201270610A1 (ru) Хинуклидиновые соединения как альфа-7 лиганды ацетилхолинового рецептора
DE602007005225D1 (de) Modulatoren von alpha7-nikotin-acetylcholin-rezeptoren und therapeutische anwendungen davon
KR102471059B1 (ko) 장애의 치료를 위한 하이드록시노르케타민 유도체
WO2012038850A8 (en) Pyrimidones for treatment of potassium channel related diseases
EA201591199A1 (ru) Бензазепины в качестве лигандов серотониновых 5-ht-рецепторов и их применение
EA201170549A1 (ru) Комбинированная терапия с использованием блокаторов рецепторов ангиотензина и антагонистов рецепторов вазопрессина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU